Results 61 to 70 of about 57,565 (259)

Malignant Mesothelioma [PDF]

, 2012
This book brings together the knowledge of eminent experts in the field of malignant mesothelioma, a highly invasive tumor of mesothelium that is the protective lining covering several body cavities.

core   +2 more sources

New Insights in Pleural Mesothelioma Classification Update: Diagnostic Traps and Prognostic Implications

Diagnostics, 2022
The 2021 WHO Classification of Tumors of the Pleura has introduced significant changes in mesothelioma codification beyond the three current histological subtypes—epithelioid, sarcomatoid and biphasic.
Maria Giovanna Mastromarino, Alessandra Lenzini, Vittorio Aprile, Greta Alì, Diana Bacchin, Stylianos Korasidis, Marcello Carlo Ambrogi, Marco Lucchi   +7 more
doaj   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial

Nature Communications
Leveraging adaptive tumour immunity to control mesothelioma via immune checkpoint blockade is now a standard therapeutic approach. However, the determinants of sensitivity remain elusive.
Dean A. Fennell, Kayleigh Hill, Min Zhang, Charlotte Poile, Sean Ewings, Essa Y. Baitei, Joanna Dzialo, Nada Nusrat, Jan Rogel, Daniel Faulkner, Christian Ottensmeier, Raffaele Califano, Gerard G. Hanna, Sarah Danson, Nicola Steele, Mavis Nye, Lucy Johnson, Kim Mallard, Joanne Lord, Calley Middleton, Peter Szlosarek, Sam Chan, Liz Darlison, Peter Wells-Jordan, Cathy Richards, James Harber, Aleksandra Bzura, Jake Spicer, Catrin Pritchard, Tamihiro Kamata, Jens C. Hahne, Maymun Jama, Edward J. Hollox, Jason F. Lester, Jin-Li Luo, Zisen Zhou, Hongji Yang, Huiyu Zhou, Astero Klampatsa, Gareth O. Griffiths   +39 more
doaj   +1 more source

Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation

Case Reports in Oncological Medicine, 2013
Introduction. Pleural mesothelioma with metastasis to the subcutaneous tissue of the abdominal wall at first diagnosis and without penetration into the peritoneum is an extremely rare clinical presentation. Methods.
R. F. Falkenstern-Ge, M. Kimmich, S. Bode-Erdmann, G. Friedel, G. Ott, M. Kohlhäufl   +5 more
doaj   +1 more source

ARTISTIC: A randomised trial of human papillomavirus (HPV) testing in primary cervical screening [PDF]

, 2009
The official published version of the article can be found at the link below.Objectives: Primary cervical screening uses cytology to detect cancer precursor lesions [cervical intraepithelial neoplasia stage 3 or beyond (CIN3+)]. Human papillomavirus (HPV)
ARTISTIC Trial Study Group, Stoykova, B, Roberts, C, J Peto, B Stoykova, M Desai, M Almonte, Almonte, M., Roberts, C., Desai, M, Kitchener, H. C., Desai, M., Gilham, C, HC Kitchener, Sargent, A., Sargent, A, Peto, J, Kitchener, HC, A Sargent, R Dowie, Gilham, C., Stoykova, B., C Roberts, Almonte, M, J Peto,, Dowie, R, Dowie, R., Peto, J., C Gilham   +28 more
core   +1 more source

Tumor‐Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T‐Cell Infiltration and Limiting Myeloid Cell‐Mediated Immunosuppression

Advanced Science, EarlyView.
ARHGEF3 is broadly downregulated across human cancers and correlates with patient prognosis. Tumor‐intrinsic ARHGEF3 activates the RHOA–ROCK–PTEN cascade to inhibit AKT signaling, thereby promoting chemokine‐driven T‐cell infiltration and relieving lipid‐mediated myeloid immunosuppression.
Yue Li, Lan Wang, Zihao Zhang, Chunmei Qian, Ning Li, Wei Huang, Qian Ba, Xiaojian Liu, Mayu Sun   +8 more
wiley   +1 more source

Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma

Journal of Translational Medicine, 2023
Mesothelioma is a cancer typically caused by asbestos. Mechanistically, asbestos carcinogenesis has been linked to the asbestos-induced release of HMGB1 from the nucleus to the cytoplasm, where HMGB1 promotes autophagy and cell survival, and to the ...
Michele Carbone, Michael Minaai, Yasutaka Takinishi, Ian Pagano, Haining Yang   +4 more
doaj   +1 more source

Advances in Cancer Immunotherapy for Solid Tumors

Advanced Science, EarlyView.
Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz, Harriet M. Kluger   +1 more
wiley   +1 more source

Circulating SMRP and CA‐125 before and after pleurectomy decortication for pleural mesothelioma

Thoracic Cancer
Background Tumor recurrence remains the main barrier to survival after surgery for pleural mesothelioma (PM). Soluble mesothelin‐related protein (SMRP) and cancer antigen 125 (CA‐125) are established blood‐based biomarkers for monitoring PM.
Juuso Paajanen, Ahmed Sadek, William G. Richards, Yue Xie, Emanuele Mazzola, Kristina Sidopoulos, John Kuckelman, Ritu R. Gill, Raphael Bueno   +8 more
doaj   +1 more source